Leadership
Eurofins Transplant Genomics is spearheaded by a passionate, hardworking, Executive Leadership Team. Click below to learn more.
Neal Beswick
Neal joined Transplant Genomics in August 2020 and is the VP of commercial operations. Neal has worked in the commercial transplant field for over 15 years focused on advanced preservation systems for all solid organs and molecular biomarkers for the kidney and liver during his 4 year tenure at Transplant Genomics. The transplant field and more specifically the pursuit of improving patient outcomes post-transplant is a passion for Neal where knowledge and imagination can fuel much needed innovation in guiding monitoring and therapy titration.
Vice President of Commercialization
Jennifer Brockmeier
.
Senior Finance Manager
Steve Kleiboeker, DVM, PhD
Steve Kleiboeker, DVM, PhD, Vice President of Research and Development, is responsible for the scientific direction and oversight of the Company’s research and development programs. Dr. Kleiboeker’s research focuses on diagnostic virology, immunology and infectious diseases as well as transplant monitoring. He is board certified as a high-complexity laboratory director, technical supervisor and clinical consultant by the American Board of Bioanalysis. Dr. Kleiboeker received his PhD and DVM from the University of Missouri.
Vice President of Research and Development & Lab Director
Chris McCloskey
Chris McCloskey brings over 20 years of executive leadership in diagnostics and precision medicine to Eurofins Transplant Genomics, with more than a decade of deep expertise in transplantation. Most recently, as Executive Vice President at PIRCHE AG, he held full general management oversight of the company’s AI-based precision medicine platform, directing go-to-market strategy and establishing partnerships with leading academic medical centers and biopharma companies. Previously, as Senior Director at Thermo Fisher Scientific, Chris served as General Manager with full P&L accountability for the company’s transplant laboratory services business. Prior to joining Thermo Fisher, Chris co-founded ActiCare Health, launching the world’s first bluetooth-enabled at-home monitoring platform for cardiothoracic transplant recipients. He also held senior-level corporate finance and marketing roles at Alere (now Abbott Rapid Diagnostics), where he led strategic planning, M&A diligence, and investor relations initiatives. Chris holds an MPH from Harvard University and a BA from the University of Pennsylvania.
President